Jin Lu, Li Yifan, He Tao, Hu Jia, Liu Jiaju, Chen Mingwei, Shi Min, Jiang Zhimao, Yang Shangqi, Mao Xiangming, Gui Yaoting, Lai Yongqing
Department of Urology, Peking University Shenzhen Hospital, Shenzhen, Guangdong 518036, P.R. China.
Department of Urology, Anhui Medical University, Hefei, Anhui 230032, P.R. China.
Mol Med Rep. 2017 Apr;15(4):1837-1846. doi: 10.3892/mmr.2017.6197. Epub 2017 Feb 13.
microRNAs (miRs) have been investigated as a novel class of regulators of cellular processes, including proliferation, apoptosis and metabolism. In particular, miR‑30b has been demonstrated to be deregulated in certain types of cancer, including lung, colorectal and gastric cancer. Previous studies of miR‑30b in renal clear cell carcinoma demonstrated that the expression level of miR‑30b was associated with distant metastasis. However, the function of miR‑30b in renal cell carcinoma (RCC) remained to be elucidated. In the present study, the expression of miR‑30b in 31 paired RCC tissues from four cell lines (786‑O, 769‑P, ACHN and 293T) was detected by reverse transcription‑quantitative polymerase chain reaction. In addition, the effect of miR‑30b on cell proliferation in RCC cells was also determined using MTT and Cell Counting Kit‑8 assay analyses. Furthermore, the function of miR‑30b in cell migration and invasion was determined by wound scratch and Transwell assays. Flow cytometry was also performed to quantify the effect of miR‑30b on cell apoptosis. The results of the current study indicated that miR‑30b was upregulated in RCC tissues from affected cell lines when compared with adjacent normal tissues and a normal kidney cell line, which is different to the downregulation of miR‑30b as observed in other types of cancer. miR‑30b is associated with RCC cell proliferation, invasion, migration and apoptosis, which indicated that miR‑30b acts as an oncogene in RCC. To the best of our knowledge, the present study is the first to demonstrate the upregulation of miR‑30b in RCC tissues and describe miR‑30b as an oncogene in RCC in the regulation of cell proliferation, migration, invasion and apoptosis. Further studies will define the target gene of miR‑30b in RCC and investigate the potential role of miR‑30b as a biomarker for RCC.
微小RNA（miR）已被作为一类新型的细胞过程调节因子进行研究，这些过程包括增殖、凋亡和代谢。特别是，已证明miR-30b在某些类型的癌症中表达失调，包括肺癌、结直肠癌和胃癌。先前关于miR-30b在肾透明细胞癌中的研究表明，miR-30b的表达水平与远处转移有关。然而，miR-30b在肾细胞癌（RCC）中的功能仍有待阐明。在本研究中，通过逆转录-定量聚合酶链反应检测了来自四种细胞系（786-O、769-P、ACHN和293T）的31对RCC组织中miR-30b的表达。此外，还使用MTT和细胞计数试剂盒-8分析确定了miR-30b对RCC细胞增殖的影响。此外，通过伤口划痕和Transwell分析确定了miR-30b在细胞迁移和侵袭中的功能。还进行了流式细胞术以量化miR-30b对细胞凋亡的影响。当前研究结果表明，与相邻正常组织和正常肾细胞系相比，受影响细胞系的RCC组织中miR-30b上调，这与在其他类型癌症中观察到的miR-30b下调不同。miR-30b与RCC细胞增殖、侵袭、迁移和凋亡相关，这表明miR-30b在RCC中作为癌基因发挥作用。据我们所知，本研究首次证明RCC组织中miR-30b上调，并将miR-30b描述为RCC中调节细胞增殖、迁移、侵袭和凋亡的癌基因。进一步的研究将确定miR-30b在RCC中的靶基因，并研究miR-30b作为RCC生物标志物的潜在作用。
